Can We Use the Silodosin as Second Line Treatment of Benign Prostate
Hyperplasia?
Abstract
Objective: Our study aimed to the efficacy of silodosin in patients with
LUTS associated with BPH who were not-responder to previous ARs blocker
therapy. Methods: Patients who did not benefit from alpha blockers
treatment, but did not want surgical treatment are included in this
study. At enrollment, 75 patients and 75 patients were assigned to group
1 and group 2, respectively. Group 1 received silodosin 8 mg, group 2
received their previous α blocker. Results: Although, in group 1 mean
IPSS score at baseline was 20,81±0,97, and it significantly decreased to
17,12±1,25 at third months, in group 2 no significant changes were
observed. On the other hand in group 1 a decrease was also observed for
both IPSS sub score was significantly reduced at third months, when it
is compared with baseline. At the end of the third month, a significant
improvement in this parameter was observed after switching to silodosin,
as compared with first value (p< 0,05). As to the residual
urine, significant improvement was observed in the silodosin group but
no significant improvement was observed in group 2. Conclusion: This
study was conducted to investigate the effectiveness and safety of
silodosin in patients with BPH who had not achieved satisfactory symptom
control with other α blockers in routine clinical practice before
surgical treatment. Thus, at least patients who have different
comorbidities will be protected from morbidities of surgery.